No Admire for Aducanumab From FDA Advisers
An FDA advisory committee voted overwhelmingly in opposition to the information offered about the controversial Alzheimer’s drug candidate aducanumab Friday. The agency’s Peripheral and Central Worried Machine (PCNS) Medicine Advisory Committee acknowledged the sure results considered in regarded as one…